Original Contributions |
From the Cardiovascular Research Center and Cardiac Unit (R.E.G., A.R.), Massachusetts General Hospital, Boston; the Vascular Research Division (Y.-C.L., H.T.D., M.A.G., F.W.L.), Department of Pathology, Brigham and Women's Hospital, Boston, Mass; the Department of Medicine and Gladstone Institute of Cardiovascular Disease (D.A.D.), UCSF, San Francisco, Calif; Universidad Complutense (C.C.), Madrid, Spain; Servicio de Inmunologia (F.S.-M.), Hospital de la Princesa, Madrid, Spain; and the Department of Microbiology/Immunology (K.S., G.K.), Northwestern University Medical School, Chicago, Ill.
Correspondence to Dr F.W. Luscinskas, Vascular Research Division, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115. E-mail fluscinska{at}rics.bwh.harvard.edu
| Abstract |
|---|
|
|
|---|
1.5 dyne/cm2. Although VCAM-1
supported only firm adhesion of lymphocytes, it was able to mediate
monocyte rolling, firm adhesion, and transmigration when expressed in
the context of otherwise unactivated vascular
endothelium. VCAM-1transduced HUVECs supported the
adhesion of as many as 4-fold more monocytes than T cells under laminar
flow. The greater monocyte adhesion was explained at least in part by
leukocyte-leukocyte interactions (secondary adhesions), which were not
seen with T cells. These secondary monocyte interactions were
specifically blocked by monoclonal antibodies to L-selectin and
P-selectin glycoprotein ligand-1. These data demonstrate that VCAM-1
expressed in the context of unactivated vascular
endothelium supports the adhesion of the leukocyte
populations present in atherosclerotic plaque and may contribute to
the predominance of monocytes over lymphocytes.
Key Words: adenovirus adhesion atherosclerosis mononuclear leukocyte
| Introduction |
|---|
|
|
|---|
80% of the leukocytes in atherosclerotic
plaque. Lymphocytes constitute 5% to 20% of this cell population and
are predominantly CD4+
CD45RO+ (memory) T cells.2
Monocytes may contribute both to the development of atherosclerotic
lesions and to events, such as acute plaque rupture, underlying acute
coronary syndromes.3 VCAM-1 supports the adhesion of mononuclear leukocytes, including monocytes and lymphocytes, in simple in vitro assays.4 It is expressed on the surface of endothelial cells during atherogenesis in animal models and is also detectable in human atherosclerotic lesions.4 5 The expression of VCAM-1 in human atherosclerotic plaques appears to be correlated with increased accumulation of mononuclear cells.6
To address the role of VCAM-1 in mononuclear cell adhesion, we generated a recombinant adenovirus containing the seven-domain isoform of rVCAM-1 (AdRSVrVCAM-1). Unlike more traditional methods of gene transfer, recombinant adenoviruses confer high-efficiency and high-level gene transduction in HUVECs, a well-characterized in vitro model of human vascular endothelium. We have also shown that adenoviral gene transfer does not globally activate HUVECs.7 Previous studies performed with immobilized VCAM-1 protein on plastic suggested that VCAM-1 alone, in the absence of an initial interaction with selectins, could support the adhesion and subsequent rolling of lymphocytes (unfractionated T cells) under flow.8 9 Using adenoviral gene transfer, we have shown that VCAM-1 alone, expressed on the surface of vascular endothelium, can support the adhesion of memory T cells, the predominant lymphocyte in the atherosclerotic plaque.7 In contrast to the experiments using purified proteins immobilized on plastic, memory T cells did not roll on the AdRSVrVCAM-1transduced endothelium but remained firmly adherent at the site of attachment. This raises the possibility that immobilized protein may not fully reflect the endothelial milieu. Together, these studies constitute an exception to the previously accepted paradigm that initial leukocyte adhesion events are selectin-mediated and that adhesion molecules of the immunoglobulin family participate only later in the multistep cascade. These data support the hypothesis that the increased VCAM-1 expression observed in the atherosclerotic plaque may be an important contributor to lymphocyte recruitment. However, these studies do not establish a role for VCAM-1 in monocyte recruitment under flow conditions. Moreover, they do not address whether VCAM-1 contributes to the impressive numerical predominance of monocytes over lymphocytes in atherosclerotic plaques.
In the present study, we extend our observations using AdRSVrVCAM-1transduced endothelium to study the adhesion of monocytes under physiological flow conditions. Recently published data from antibody-blocking experiments under flow conditions have shown roles only for L- and P-selectin in the initial attachment of monocytes to TNF-activated endothelial cells.10 Antibody-blocking experiments on globally activated endothelium, however, cannot address the important question of whether VCAM-1 expressed in isolation is sufficient to support the adhesion of monocytes. In the present study, we also assess quantitative differences between the adhesion of monocytes and Jurkat T cells (T-cell line with adhesion properties similar to CD4+ memory T lymphocytes) to VCAM-1, the role of monocyte-monocyte interactions in adhesion, and how the observed differences in adhesion could contribute to the predominance of monocytes in the atherosclerotic plaque.
| Materials and Methods |
|---|
|
|
|---|
was obtained from Biogen.
Cell Culture
The 293 cell line was obtained from the American Type Culture
Collection and cultured in DMEM supplemented with 10% FBS as
previously described.11 The Jurkat T-cell line
(JS-10) was cultured under the same conditions and was the gift of Dr
Lloyd Stoolman (University of Michigan, Ann Arbor). HUVECs were
isolated from several normal-term umbilical veins, pooled, and cultured
on 0.1% gelatincoated tissue culture dishes as
described12 in medium 199 with 20% FBS,
endothelial cell growth factor (25 µg/mL, Biomedical
Technologies), porcine intestinal heparin (50 µg/mL, Sigma Chemical
Co), and antibiotics. After infection with adenoviral vectors, HUVECs
were cultured as above, but the serum concentration was reduced to
10%. For stimulation of HUVECs, TNF-
(200 U/mL) was added as
indicated. For experimental use in the flow plate
apparatus, HUVECs (passages 1 and 2) were plated at
confluence on 25-mm fibronectincoated glass coverslips, as previously
described.13
Recombinant Adenoviruses
Two recombinant type 5 adenoviruses were used in these studies:
AdRSVß-gal and AdRSVrVCAM-1. Both viruses use the dL
32714 backbone, contain
E1/E3 deletions, and were generated as previously
described.7 15 Large-scale production of
adenovirus and determination of viral titer was accomplished as
described previously.11 Only one viral stock of
each construct was used in the course of these studies. Stock titer was
1010 pfu/mL for both vectors, with a particle/pfu
ratio of
102.
Infection of HUVECs With Adenoviral Vectors
HUVECs were plated at confluence and infected 18 hours later.
Infection was performed in 96-well plates (Costar) or on 25-mm-diameter
glass coverslips by the addition of virus diluted in 0.05 or 0.8 mL,
respectively, of infection medium (DMEM with 2% FCS) for 1 to 1.5
hours at 37°C. At that time, 0.15 or 1.5 mL of growth medium was
added to each well, and the cells were incubated for 48 hours before
evaluation.
Monoclonal Antibodies
The following mAbs have been described previously: H18/7 and
H4/1816 (to human E-selectin),
Hu5/317 (to human ICAM-1),
E1/618 (which recognizes both human and rabbit
VCAM-1), Hu8/418 (which recognizes only human
VCAM-1), Rb1/94 (which is specific for rVCAM-1),
HP2.1 (to
4-integrin, Immunotech), HPDG2/3 (to
P-selectin, Genetics Institute), TS1/18 (to CD18, American Type Culture
Collection clone HB203), HUTS2119 (which
recognizes an epitope on ß1-integrin that is
induced by cell activation), K16/1620
(IgG1 nonbinding control),
W6/3220 (IgG2 binding
control), LAM1-4 and LAM1-1410 (to L-selectin,
function blocking and nonblocking, respectively), and
KPL-121 (function blocking mAb to PSGL-1, the
best-characterized ligand for P-selectin).
Surface Immunofluorescence Assays
HUVEC monolayers in 96-well plates were incubated on ice with
the indicated primary mAb in RPMI/1% FCS at 10 µg/mL for 45 minutes.
Wells were washed three times with RPMI/1% FCS and then incubated with
an FITC-conjugated goat anti-mouse polyclonal F(ab')2 antibody (Caltag)
diluted 1:100 in Dulbecco's PBS on ice. After 45 minutes, wells were
washed twice with Dulbecco's PBS/20% FCS and twice with Dulbecco's
PBS alone. Cells were lysed with 0.01% NaOH in 0.1% SDS (pH 8.6), and
fluorescence was quantified using a CytoFluor 2350 (Perseptive
Biosystems) fluorescent plate reader set at 485 nm
(excitation)/535 nm (emission). For each flow experiment, a 96-well
plate was cultured and infected in parallel at the same multiplicity of
infection. On the day of the flow adhesion assay, a
fluorescence immunoassay was performed on this plate to
document rVCAM-1 expression and to rule out nonspecific activation of
the endothelial monolayer.
Leukocyte Isolation and Flow Cytometric Analysis
Human monocytes were purified from single donor human
platelet pheresis residues by Ficoll-Hypaque density gradient
centrifugation at 15°C (LSM, Organon Teknika),
followed by counterflow centrifugation elutriation.
Monocyte suspensions were >91% pure with 6% to 8% lymphocyte, <2%
granulocyte, and essentially no platelet contamination, as
determined by light scatter and cell surface antigen analysis
with mAbs directed to CD14, CD41, CD61, and P-selectin as detailed
previously.10 Flow cytometric analysis of
monocyte cell surface antigens was subsequently performed. Binding of
murine mAbs recognizing various monocytic surface antigens was detected
with indirect immunofluorescence using goat
FITC-labeled secondary mAb (1:100 dilution) in RPMI 1640/5% FCS. The
fluorescence of 104 cells was measured on
a FACScan (Becton Dickinson). Nonspecific fluorescence was
corrected by subtracting the mean channel fluorescence of mAb
K16/16 (nonbinding control) from the mean channel fluorescence
for each mAb used. The number of binding sites for the antibodies on
Jurkat T cells and monocytes was estimated as follows: A mixture of
8-µm microbeads (Flow Cytometry Standards Corp) with different
predetermined binding sites per bead for mouse IgG was used. The
microbeads were stained with each mAb and analyzed using the
same protocol for the cells as described above. A standardized curve
for each mAb was generated by using the ratio of the mean channel
fluorescence to binding sites. The number of binding sites for
the respective mAb on the cells was then estimated. To normalize the
number of binding sites for the different cell surface areas, cell
diameters were measured from the image on the video monitor, the ratio
of the surface areas was calculated (Jurkat T cell:monocyte surface
area ratio, 1.54:1), and the number of T-cell binding sites was
adjusted accordingly.
Adhesion Assays Under Flow: Apparatus Design and
Experimental Application
The parallel-plate flow chamber used in the present study
has been described previously in
detail.13 22 Endothelial
monolayers on coverslips were incubated with culture medium for 48 to
72 hours after viral infection. Where indicated, monolayers were
stimulated with TNF-
(200 U/mL) for 4 hours. For blocking
experiments, immediately before the assay, HUVEC monolayers were
incubated with culture medium containing the indicated mAb or culture
medium alone for 30 minutes at 37°C. The coverslip was positioned in
the flow chamber, and the entire chamber was then mounted on an
inverted microscope equipped with x10, x20, and x40 phase-contrast
objectives. Leukocytes were incubated with a saturating concentration
of the indicated mAb for 20 minutes at 4°C and diluted with perfusion
medium to 106 cells/mL. The mAb concentration was
adjusted to saturating levels in perfusion medium, and leukocytes were
drawn through the chamber at controlled flow rates. The cells were
perfused at an estimated shear stress of 1.5
dyne/cm2 (flow rate, 0.78 mL/min) for 3 minutes,
and when indicated, the flow rate was then decreased by 0.5
dyne/cm2 every 3 minutes to 0.5
dyne/cm2. The entire period of perfusion was
recorded on videotape using a video recorder equipped with a
time-date generator with a millisecond clock. Leukocyte adhesion was
quantified as follows: Total accumulation of leukocytes was determined
by counting the number of T cells or monocytes in five to seven
randomly selected x20 or x40 microscope fields during the final 2
minutes at each level of flow. To allow comparison between experiments,
all data obtained with the x40 objective were multiplied by the ratio
of the x20/x40 field areas (ie, 4.46). Interaction rates were
determined by counting the number of leukocytes that entered a x40
field and were captured (either transiently or permanently) by another
leukocyte or endothelial cell per minute. Primary and
secondary adhesion events were quantified by counting the number of
cells entering and adhering to the endothelium in a
x10 field at 1.5 dyne/cm2 over 5 minutes and
differentiating whether the initial interaction was
leukocyte-endothelialor leukocyte-leukocytemediated
by replaying the videotape in slow motion several times, similar to the
strategy used by Alon et al.23 For these
analyses, the field of view was as close to the inlet port as
possible to avoid cell depletion and to allow documentation of the
trajectory of entering leukocytes.
Statistical Analysis
Data are expressed as the mean±SD or mean±SEM, as indicated.
Statistical comparison of means was performed by two-tailed unpaired
Student t test or ANOVA, as indicated. The null hypothesis
was considered rejected at P<0.05.
| Results |
|---|
|
|
|---|
2.0
dyne/cm2, further studies were performed at flow
rates of
1.5 dyne/cm2. For the initial 3
minutes of the experiment, the cells were perfused at a shear stress of
1.5 dyne/cm2. This was subsequently decreased by
0.5 dyne/cm2 at 3-minute intervals to the final
shear stress of 0.5 dyne/cm2. As seen in Figure 1
|
To verify the specificity of the observed interactions, monoclonal
blocking experiments were performed (Figure 1
). A mAb (HP2.1) to the
VCAM-1 counterligand (the
4-integrin) ablated
monocyte adhesion to AdRSVrVCAM-1transduced HUVECs. Monocyte adhesion
was also blocked by Rb1/9, a function-blocking mAb specific for
rVCAM-1. Therefore, adhesion was mediated by the adenovirally expressed
rVCAM-1 rather than endogenous human VCAM-1 or fibronectin,
which can also support
4-integrindependent
adhesion. In contrast, mAbs to the ß2-integrins
(mAb TS1/18), the best characterized counterreceptor for
endothelial ICAM-1, or to P-selectin (mAb HPDG 2/3) did
not block adhesion.
Monocyte Adhesion Exceeds Jurkat T-Cell Adhesion
The JS-10 Jurkat T-cell line, which expresses high levels of
4-integrins, was used to compare monocyte and
T-cell adhesion. We have previously shown that VCAM-1 supports the same
level of adhesion of the JS-10 Jurkat T-cell line and memory
CD4+ CD45RO+ T
lymphocytes.7 In contrast, Jurkat T-cell adhesion
to AdRSVrVCAM-1transduced HUVECs was significantly less than monocyte
adhesion (Figure 2
). This was most
notable at the highest level of shear examined (1.5
dyne/cm2), where monocyte adhesion was 4-fold
higher than Jurkat T-cell adhesion. We again verified that Jurkat
T-cell adhesion was entirely abolished by antiVCAM-1 mAb and by a mAb
directed against
4-integrins (data not
shown).
|
Role of Monocyte-Monocyte Interactions
In addition to interacting primarily with
endothelial cells, leukocytes can also bind secondarily
to leukocytes already adherent to the endothelium. Such
secondary attachment has been reported to occur through an
L-selectindependent mechanism and has been best characterized for
neutrophils and lymphocytes.23 Therefore, we next
examined monocyte-monocyte interactions and their impact on overall
monocyte adhesion to AdRSVrVCAM-1transduced monolayers. Monocyte
adhesion over 5 minutes at 1.5 dyne was reduced by either a blocking
mAb to L-selectin or a blocking mAb to PSGL-1 (a P-selectin ligand) or
both (Figure 3a
). In contrast, adhesion
was not influenced by a control antibody, by a nonblocking mAb to
L-selectin, or by a combination of both compared with medium alone. We
next determined whether the decrease in adherent monocytes seen with
blocking antibodies to L-selectin and PSGL-1 was due to a diminution in
monocyte-monocyte interactions or primary interactions with the
endothelium. In Figure 3b
, we quantified the number of
cells entering and adhering to the endothelium in a
x10 field, differentiating whether the initial interaction was
leukocyte-leukocyte or leukocyte-endothelial. Blocking
mAbs LAM1-4 and KPL-1 (or their combination) markedly reduced secondary
adhesion of monocytes, whereas primary adhesion remained relatively
unaffected. Jurkat T cells did not form secondary adhesions at any
level of shear tested.
|
Analysis of Monocyte and Jurkat T-Cell Surface
Antigens
Flow cytometric analysis of monocyte and Jurkat T-cell
surface antigens was performed to gain insight into quantitative and
qualitative differences in adhesion (Table
). Jurkat T
cells and monocytes exhibited similar levels of
4-integrins. Expression of the
ß1-integrin activation epitope, as detected by
mAb HUTS21, was present, albeit low, on both cell types. Of note,
the levels of L-selectin and PSGL-1 were significantly greater on
monocytes. These data suggest that both Jurkat T cells and monocytes
express activated ß1-integrins but that
the levels of L-selectin and PSGL-1 are lower on Jurkat cells compared
with monocytes. Thus, both cell types can use
4-integrins to initially attach and arrest on
VCAM-1. However, monocytes are also able to accumulate through
monocyte-monocyte interactions; this accumulation of monocytes appears
to be functionally related to their increased surface expression of
L-selectin and PSGL-1 (Figure 3
and Table
).
|
Monocyte Adhesion to TNF-Stimulated Versus AdRSVrVCAM-1Transduced
HUVECs: Differences in Initial Attachment Rates
As previously described, adhesion of either memory T cells or the
Jurkat JS-10 cell line under flow to VCAM-1transduced HUVECs was not
significantly different from adhesion to TNF-activated
HUVECs.7 In contrast, overall monocyte adhesion
to AdRSVrVCAM-1transduced monolayers was far less than that seen with
TNF-activated HUVECs (Figure 4
).
To gain insight into these differences, we quantified monocyte initial
interaction rates by counting the number of monocytes that entered a
x40 field and were captured (either transiently or permanently) by
adherent monocytes or endothelial cells (Figure 5
). The interaction rates of monocytes to
TNF-activated HUVECs significantly exceeded the rate of
attachment to AdRSVrVCAM-1transduced HUVECs at only the highest level
of shear examined. Interestingly, in both cases the number of
interactions between monocytes and the endothelial
monolayer decreased over time as the shear level was decreased. This
may be due to monocyte transmigration that transpires over the time it
takes to complete the experimental protocol of progressively lower
shear rates. Although monocytes transmigrating across the monolayer are
counted as firm adhesions, they can no longer serve as the substrate
for secondary adhesions.
|
|
As noted in our previous study,7 T cells initially attached
but subsequently did not roll downstream at any flow level examined.
Monocytes predominantly exhibited a similar phenotypic interaction with
AdRSVrVCAM-1transduced HUVECs. However, some monocyte rolling was
evident at all flow levels tested. This phenotype was not
affected by antibodies to ICAM-1 or P-selectin. Monocyte but not
lymphocyte transmigration was noted after attachment to
AdRSVrVCAM-1transduced HUVECs (Figure 6
). Monocyte rolling, firm adhesion, and
transmigration were abolished by antibodies to VCAM-1 or its
counterligand. Together, these data suggest VCAM-1 can mediate rolling,
firm attachment, and transmigration under flow conditions, when
expressed in the context of otherwise unactivated vascular
endothelium.
|
| Discussion |
|---|
|
|
|---|
4-integrin) or to
rVCAM-1 but was unaffected by mAb blockade of P-selectin or
ß2-integrins. These results demonstrate that
VCAM-1 alone is sufficient to support adhesion and transmigration of
monocytes across vascular endothelial cells under
laminar flow at shear levels up to 1.5
dyne/cm2.
The present study is the first, to our knowledge, to compare
quantitative differences between T-cell and monocyte adhesion to
endothelium expressing VCAM-1 in the absence of overt
endothelial activation and the expression of other
inducible adhesion molecules. We have previously shown that VCAM-1
supports the same level of adhesion of memory T cells and the JS-10
Jurkat T-cell line.7 In contrast, monocyte
adhesion to VCAM-1transduced endothelial cells
significantly exceeds T-cell adhesion at all levels of shear examined
and was as much as 4-fold greater at 1.5
dyne/cm2. The greater monocyte adhesion was
explained, at least in part, by leukocyte-leukocyte interactions
(secondary adhesions), which were not seen with either the Jurkat cell
line or primary memory T cells.7 The difference
between monocyte and T-cell adhesion was greatest at the highest level
of shear examined, where secondary adhesion may contribute more to
overall adhesion than it does at lower levels of
shear.23 Secondary adhesion of monocytes was
dependent on L-selectin and the P-selectin ligand, PSGL-1. The lack of
lymphocyte secondary tethering may reflect either the absence of
L-selectin ligand on primary T cells23 24 or the
greatly reduced expression of L-selectin and PSGL-1 (Table
) as seen in
the JS-10 Jurkat T-cell line. In either case, the absence of secondary
tethering appears to be an important qualitative and quantitative
difference between T-cell and monocyte adhesion under flow in
vitro.
Interestingly, although VCAM-1 supported only firm adhesion of lymphocytes in this system, it was able to mediate monocyte rolling, firm adhesion, and transmigration when expressed in the context of otherwise unactivated vascular endothelium. Although adhesion molecules are sometimes categorized as mediating only one kind of adhesive interaction, these data suggest that VCAM-1 can mediate or contribute to multiple phenotypic interactions of monocytes with vascular endothelium. Lymphocytes appear to require additional signals present in activated endothelium for transmigration. Monocytes, in contrast, will progress to transmigration after initial VCAM-dependent tethering even in the absence of global activation of endothelial cells. VCAM-1 is more effective at mediating the initial attachment of monocytes than of lymphocytes. In addition, it is sufficient to initiate events culminating in monocyte, but not lymphocyte, transmigration. Together, these data suggest that stimuli inducing vascular VCAM-1 expression in vivo25 may initiate events leading to monocyte accumulation in the vessel wall and contribute to the predominance of monocytes in atherosclerotic lesions. Of note, the prevalence of monocytes and memory T cells in peripheral blood is comparable.26 In addition, differences in monocyte-versus-lymphocyte survival, proliferation, or egress may also influence the relative numbers of these cells in lesions.
We have also shown previously that memory T-cell adhesion to
AdRSVrVCAM-1transduced endothelium is quantitatively
similar to lymphocyte adhesion to TNF-
stimulated
endothelium (4 hours, 200 U/mL).7
Therefore, the majority of memory lymphocyte adhesion to
TNF-
stimulated endothelium can be quantitatively
accounted for by VCAM-1dependent adhesion.20 In
contrast, monocyte adhesion to TNF-
activated
endothelium was much greater than to
AdRSVrVCAM-1transduced HUVECs. Insight into these differences in the
level of adhesion can be found by comparing the rates of initial
monocyte interaction (Figure 5
). Of note, the initial rate of monocyte
attachment to TNF-
activated HUVECs significantly exceeds
attachment to AdRSVrVCAM-1transduced HUVECs only at relatively high
shear (1.5 dyne/cm2). At this flow level, VCAM-1
alone supports initial attachment of monocytes less effectively than
does VCAM-1 in concert with the other adhesion molecules expressed by
activated HUVECs. It seems likely that the selectins, absent
from AdRSVrVCAM-1transduced monolayers, contribute significantly to
the initial attachment of monocytes to TNF-
stimulated HUVECs at
this level of shear. At 1.0 and 0.5 dyne/cm2,
there was no significant difference between the attachment rates of
monocytes to TNF-
activated compared with
AdRSVrVCAM-1transduced HUVECs. This suggests that at 1.0 and 0.5
dyne/cm2, VCAM-1 alone is able to support initial
monocyte attachment as effectively as all the adhesion molecules
expressed by TNF-
activated HUVECs, including the
selectins. Interestingly, at these lower flow levels,
TNF-
stimulated HUVECs still support significantly greater overall
firm adhesion of monocytes than do AdRSVrVCAM-1transduced HUVECs.
Therefore, at these lower flow rates, the smaller number of firmly
adherent monocytes seen on AdRSVrVCAM-1transduced
endothelium primarily reflects the failure of initially
interacting monocytes to remain adherent. On the basis of these data,
we would hypothesize that coexpression of E- or P-selectin with VCAM-1
might further enhance monocyte accumulation at 1.5
dyne/cm2 or even higher flow but have less effect
at lower shear, where initial attachment is already comparable to
TNF-
activated endothelium. At 0.5 to 1.0
dyne/cm2, the addition of molecules that further
enhance firm adhesion, such as ICAM-1, would more likely increase
monocyte accumulation. Finally, because the majority of T-cell adhesion
to TNF-
stimulated endothelium can be
quantitatively accounted for by VCAM-1dependent adhesion, we further
hypothesize that concomitant expression of other adhesion molecules or
cytokines in our system will augment even more dramatically the
differences between monocyte and lymphocyte adhesion.
The in vitro experiments presented here demonstrate monocyte adhesion at shear levels up to 1.5 dyne/cm2, a level comparable to those used in other in vitro flow studies.13 In vivo, multiple physical and biological factors not present in our flow chamber are thought to augment leukocyte adhesion at higher levels of shear.27 In addition, the shear forces used in the present study are comparable to those found in intimal neovascular microvessels present in atherosclerotic plaques. These microvessels may provide an important portal of entry for leukocytes into the arterial wall. VCAM-1 expression is more prevalent on the neovasculature than on the luminal endothelium in human atherosclerosis.6 Moreover, neovascular VCAM-1 expression correlates with increased intimal lymphocyte and macrophage accumulation.6 Extrapolation of our in vitro results to the in vivo setting will require further investigation in animal models of leukocyte trafficking. Adenoviral gene transfer in animal models that use intravital microscopy could be used to directly address possible causal relationships between VCAM-1 expression and monocyte recruitment in vivo.
These data demonstrate that VCAM-1 supports the adhesion of the primary leukocyte populations present in atherosclerotic plaque and may contribute to the quantitative predominance of monocytes over lymphocytes. Adenoviral gene transfer can serve as the basis for a useful model to reconstitute and thus define the endothelial signals important in monocyte recruitment. Dissecting the role of these molecules in monocyte recruitment may have important clinical implications.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received December 1, 1997; accepted February 25, 1998.
| References |
|---|
|
|
|---|
2.
Stemme S, Holm J, Hansson GK. T lymphocytes in human
atherosclerotic plaques are memory cells expressing CD45RO and the
integrin VLA-1. Arterioscler Thromb. 1992;12:206211.
3.
Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V,
Fallon JT. Macrophage infiltration in acute coronary
syndromes: implications for plaque rupture. Circulation. 1994;90:775778.
4.
Cybulsky MI, Gimbrone MA. Endothelial
expression of a mononuclear leukocyte adhesion molecule during
atherogenesis. Science. 1991;251:788791.
5. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223229.[Medline] [Order article via Infotrieve]
6.
O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers
CE. Neovascular expression of E-selectin, intercellular adhesion
molecule-1, and vascular cell adhesion molecule-1 in human
atherosclerosis and their relation to intimal leukocyte
content. Circulation. 1996;93:672682.
7.
Gerszten RE, Luscinskas FW, Ding HT, Dichek DA,
Stoolman LM, Gimbrone MA Jr, Rosenzweig A. Adhesion of memory
lymphocytes to VCAM-1transduced human vascular
endothelial cells under simulated
physiological flow conditions in vitro. Circ
Res. 1996;79:12051215.
8.
Berlin C, Bargatze RF, Campbell JJ, von Andrian UH,
Szabo MD, Hasslen SR, Nelson RD, Berg EL, Erlandsen SL, Butcher EC.
4 integrins mediate lymphocyte attachment and rolling under
physiologic flow. Cell.. 1995;80:413422.[Medline]
[Order article via Infotrieve]
9.
Alon R, Kassner PD, Carr MW, Finger EB, Hemler ME,
Springer TA. The integrin VLA-4 supports tethering and rolling in flow
on VCAM-1. J Cell Biol. 1995;128:12431253.
10. Luscinskas FW, Ding H, Tan P, Cumming D, Tedder T, Gerritsen ME. L- and P-selectins, but not CD49d (VLA4) integrins, mediate monocyte initial attachment to TNF-activated vascular endothelium in vitro. J Immunol. 1996;156:326335.
11. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, ed. Gene Transfer and Expression Protocols. Clifton, NJ: Humana Press Inc; 1991;7:109128.
12. Gimbrone MA Jr. Culture of vascular endothelium. Prog Hemost Thromb. 1976;3:128.[Medline] [Order article via Infotrieve]
13.
Luscinskas FW, Kans GS, Ding H, Pizcueta P,
Schleiffenbaum BE, Tedder TF, Gimbrone MA. Monocyte rolling, arrest and
spreading on IL-4-activated vascular
endothelium under flow is mediated via sequential
action of L-selectin, ß1-integrins, and ß2 integrins.
J Cell Biol.. 1994;125:14171427.
14. Galos RS, Williams J, Shenk T, Jones N. Physical location of host-range mutations of adenovirus type 5: deletion and marker-rescue mapping. Virology. 1980;104:510513.[Medline] [Order article via Infotrieve]
15.
Dong G, Schulick AH, DeYoung MB, Dichek DA.
Identification of a cis-acting sequence in the human
plasminogen activator inhibitor
type-1 gene that mediates transforming growth factor-ß1
responsiveness in endothelium in vivo. J
Biol Chem.. 1996;271:2996929977.
16.
Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS,
Gimbrone MA. Identification of an inducible
endothelial-leukocyte adhesion molecule. Proc
Natl Acad Sci U S A. 1987;84:92389242.
17. Luscinskas FW, Cybulsky MI, Kiely JM, Peckins CS, Davis VM, Gimbrone MA. Cytokine-activated human endothelial monolayers support enhanced neutrophil transmigration via a mechanism involving both endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule-1. J Immunol. 1991;146:16171625.[Abstract]
18.
Taichman DB, Cybulsky MI, Djaffar I, Longenecker BM,
Teixido J, Rice GE, Aruffo A, Bevilacqua MP. Tumor cell surface
4 ß1 integrin mediates adhesion to vascular
endothelium: demonstration of an interaction with the
N-terminal domains of INCAM-110/VCAM-1. Cell Regul.. 1991;2:347355.[Medline]
[Order article via Infotrieve]
19.
Luque A, Gomez M, Puzon W, Takada Y,
Sánchez-Madrid F, Cabañas C. Activated
conformations of very late activation integrins detected by a group of
antibodies (HUTS) specific for a novel regulatory region (355425) of
the common ß1 chain. J Biol Chem. 1996;271:1106711075.
20.
Luscinskas FW, Ding H, Lichtman AH. P-selectin and
vascular cell adhesion molecule 1 mediate rolling and arrest,
respectively, of CD4+ T lymphocytes on tumor necrosis factor
alpha-activated vascular endothelium under
flow. J Exp Med. 1995;181:11791186.
21.
Goetz DJ, Greif DM, Ding H, Camphausen RT, Howes
S, Comess KM, Snapp KR, Kans GS, Luscinskas FW. Isolated P-selectin
glycoprotein ligand-1 dynamic adhesion to P- and
E-selectin. J Cell Biol. 1997;137:509519.
22.
Shen J, Luscinskas FW, Connolly A, Dewey CF Jr,
Gimbrone MA Jr. Fluid shear stress modulates cytosolic free calcium in
vascular endothelial cells. Am J
Physiol. 1992;262:C384C390.
23.
Alon R, Fuhlbrigge R, Finger E, Springer T.
Interactions through L-selectin between leukocytes and adherent
leukocytes nucleate rolling adhesion on selectins and VCAM-1 in shear
flow. J Cell Biol. 1996;135:849865.
24.
Fuhlbrigge RC, Alon R, Puri KD, Lowe JB, Springer TA.
Sialylated, fucosylated ligands for L-selectin expressed on leukocytes
mediate tethering and rolling adhesions in physiologic flow conditions.
J Cell Biol. 1996;135:837848.
25.
Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An
atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable
mononuclear leukocyte adhesion molecule, in rabbit aortic
endothelium. Arterioscler Thromb. 1993;13:197204.
26. Roederer MJ, Dubs G, Andersen MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest. 1995;95:20612066.
27. Melder RJ, Munn LL, Yamada S, Ohkubo C, Jain RK. Selectin- and integrin-mediated T-lymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes. Biophys J.. 1995;69:21312138.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Lorenowicz, J. van Gils, M. de Boer, P. L. Hordijk, and M. Fernandez-Borja Epac1-Rap1 signaling regulates monocyte adhesion and chemotaxis J. Leukoc. Biol., December 1, 2006; 80(6): 1542 - 1552. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Serebruany, A. Malinin, and R. Scott The In Vitro Effects of a Novel Vascular Protectant, AGI-1067, on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 191 - 196. [Abstract] [PDF] |
||||
![]() |
A. Kawakami, M. Aikawa, P. Alcaide, F. W. Luscinskas, P. Libby, and F. M. Sacks Apolipoprotein CIII Induces Expression of Vascular Cell Adhesion Molecule-1 in Vascular Endothelial Cells and Increases Adhesion of Monocytic Cells Circulation, August 15, 2006; 114(7): 681 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rothenbacher, S. Muller-Scholze, C. Herder, W. Koenig, and H. Kolb Differential Expression of Chemokines, Risk of Stable Coronary Heart Disease, and Correlation with Established Cardiovascular Risk Markers Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 194 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Liu, D. S. Chi, C. Li, H. K. Hall, D. M. Milhorn, and G. Krishnaswamy HIV-1 Tat protein-induced VCAM-1 expression in human pulmonary artery endothelial cells and its signaling Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L252 - L260. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-P. Chuang, Y.-F. Huang, Y.-L. Hsu, H.-S. Liu, H.-C. Chen, and C.-C. Shieh Ligation of lymphocyte function-associated antigen-1 on monocytes decreases very late antigen-4-mediated adhesion through a reactive oxygen species-dependent pathway Blood, December 15, 2004; 104(13): 4046 - 4053. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Charo and M. B. Taubman Chemokines in the Pathogenesis of Vascular Disease Circ. Res., October 29, 2004; 95(9): 858 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Tchernychev, B. Furie, and B. C. Furie Peritoneal macrophages express both P-selectin and PSGL-1 J. Cell Biol., December 8, 2003; 163(5): 1145 - 1155. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. D. Ng, S. S. Deshpande, K. Irani, and B. R. Alevriadou Adhesion of flowing monocytes to hypoxia-reoxygenation-exposed endothelial cells: role of Rac1, ROS, and VCAM-1 Am J Physiol Cell Physiol, July 1, 2002; 283(1): C93 - C102. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Cayatte, A. Rupin, J. Oliver-Krasinski, K. Maitland, P. Sansilvestri-Morel, M.-F. Boussard, M. Wierzbicki, T. J. Verbeuren, and R. A. Cohen S17834, a New Inhibitor of Cell Adhesion and Atherosclerosis That Targets NADPH Oxidase Arterioscler. Thromb. Vasc. Biol., October 1, 2001; 21(10): 1577 - 1584. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Chan, S. J. Hyduk, and M. I. Cybulsky Chemoattractants Induce a Rapid and Transient Upregulation of Monocyte {alpha}4 Integrin Affinity for Vascular Cell Adhesion Molecule 1 Which Mediates Arrest: An Early Step in the Process of Emigration J. Exp. Med., May 14, 2001; 193(10): 1149 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. May, F.-J. Neumann, A. Schomig, and K. T. Preissner VLA-4 (alpha 4beta 1) engagement defines a novel activation pathway for beta 2 integrin-dependent leukocyte adhesion involving the urokinase receptor Blood, July 15, 2000; 96(2): 506 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gyongyosi, P. Yang, A. Khorsand, D. Glogar, on behalf of the Austrian Wiktor Stent Study Group, and European Paragon Stent Investigators Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1580 - 1589. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Asimakopoulos, A. Kohn, D. C. Stefanou, D. O. Haskard, R. C. Landis, and K. M. Taylor Leukocyte integrin expression in patients undergoing cardiopulmonary bypass Ann. Thorac. Surg., April 1, 2000; 69(4): 1192 - 1197. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bonecchi, F. Facchetti, S. Dusi, W. Luini, D. Lissandrini, M. Simmelink, M. Locati, S. Bernasconi, P. Allavena, E. Brandt, et al. Induction of Functional IL-8 Receptors by IL-4 and IL-13 in Human Monocytes J. Immunol., April 1, 2000; 164(7): 3862 - 3869. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fruebis, M. Silvestre, D. Shelton, C. Napoli, and W. Palinski Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits J. Lipid Res., November 1, 1999; 40(11): 1958 - 1966. [Abstract] [Full Text] |
||||
![]() |
K. H. Han, K. O. Han, S. R. Green, and O. Quehenberger Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia: differential effects of plasma lipoproteins on monocyte function J. Lipid Res., June 1, 1999; 40(6): 1053 - 1063. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |